Table S5.

Prognostic factors of PHR, recurrence, and RFS in recent literature and our study

Study	Risk factors for PHR	Risk factors for HCC recurrence	Risk factors for RFS
Dan et al1	Without antiviral therapy and hepatic resection	–	–
Huang et al2	Without antiviral therapy and preoperative HBV DNA <103 copies/mL	–	–
Huang et al3	HBeAg positivity, HBV DNA level of ≥200 IU/mL, Ishak inflammation score of ≥3, preoperative TACE, operation time of >180 minutes, and blood transfusion	–	HBeAg positivity, HBV DNA level of ≥200 IU/mL, tumor diameter of >5 cm, presence of satellite nodules, presence of portal vein tumor thrombus, blood transfusion, resection margin of <1.0 cm, and HBV reactivation
Huang et al6	–	Tumor size of >5 cm, surgical margin of <1 cm, tumor encapsulation, presence of microsatellite nodules, and presence of microportal vein tumor thrombus	–
Lao et al7	Without antiviral therapy and hepatic inflow occlusion	–	–
Sohn et al8	Without antiviral therapy	HBeAg positivity, tumor number >1, microvascular invasion, and HBV reactivation	–
Our study	Without antiviral therapy, HBeAg positivity, HBV-cAg S1 positivity, preoperative HBV DNA level of ≥500 copies/mL, hepatic inflow occlusion, moderate liver cirrhosis or more, operating time >180 minutes, and blood transfusion	HBeAg positivity, tumor thrombus, and blood transfusion	PHR, HBeAg positivity, surgical margin <1 cm, moderate liver cirrhosis or more, and blood transfusion

Abbreviations: HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HBV-cAg S1, against hepatitis B core antigen S1; HCC, hepatocellular carcinoma; PHR, postoperative HBV reactivation; RFS, recurrence-free survival; TACE, transarterial chemoembolization.